# Efficacy and Safety of Paclitaxel for Injection (Albumin-bound) for First-line Chemotherapy of Ovarian Cancer

> **NCT03818282** · PHASE2 · UNKNOWN · sponsor: **Huazhong University of Science and Technology** · enrollment: 77 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Paclitaxel for injection (albumin-bound)

## Key facts

- **NCT ID:** NCT03818282
- **Lead sponsor:** Huazhong University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-03-01
- **Primary completion:** 2023-06-30
- **Final completion:** 2024-12-31
- **Target enrollment:** 77 (ESTIMATED)
- **Last updated:** 2019-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03818282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03818282, "Efficacy and Safety of Paclitaxel for Injection (Albumin-bound) for First-line Chemotherapy of Ovarian Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03818282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*